That’s a topic I’m very excited about. To answer this, these are the outcomes of patients before surgery, either giving them chemotherapy, which is a standard of care, or giving them endocrine therapy, which is a hormonal agent. The idea is we know historically lobular cancer does not respond well to chemotherapy. So the idea is can we use an alternative that’s not non-chemo-based, that can give the same outcomes...
That’s a topic I’m very excited about. To answer this, these are the outcomes of patients before surgery, either giving them chemotherapy, which is a standard of care, or giving them endocrine therapy, which is a hormonal agent. The idea is we know historically lobular cancer does not respond well to chemotherapy. So the idea is can we use an alternative that’s not non-chemo-based, that can give the same outcomes. What the study was for. It’s the largest study to look at those outcomes and it proved again that chemotherapy is not ideal for lobular patients with very low response rates to chemotherapy and endocrine therapy gave very encouraging results close to a 10 percent response that is very meaningful called the PEPI score of zero. So that’s very exciting to see and that’s solidify the potential of endocrine therapy to be the next frontier for the treatment of lobular breast cancer before surgery in the neoadjuvant setting as we say.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
